Trevi Therapeutics Inc $TRVI

Recent News (4)

• Trevi Therapeutics to Participate in Upcoming September Conferences GlobeNewswire · 03 Sep 2026 NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuph…
• Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 GlobeNewswire · 26 Aug 2026 Professor Marlies Wijsenbeek will give an oral presentation on the quality-of-life outcomes assessed by the LCQ from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-re…
• Raymond James raises Trevi Therapeutics price target on pipeline progress Investing.com · 07 Aug 2026 Raymond James raises Trevi Therapeutics price target on pipeline progress
• Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright Investing.com · 20 Jul 2026 Trevi Therapeutics stock price target raised to $24 by H.C. Wainwright